A guide to drug use during percutaneous coronary intervention

Drugs

Volumn 62, Issue 18, 2002, Pages 2589-2601

  Choo, Joseph K ^a   Young, John J ^a   Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDE DERIVATIVE; REVIPARIN; THIENO[3,2 C]PYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEART DISEASE; HUMAN; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; STENT; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; ASPIRIN; CLINICAL TRIALS; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INTRAOPERATIVE PERIOD; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PYRIDINES; THROMBIN;

THROMBUS;

EID: 0036963087     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262180-00003     Document Type: Review

References (78)

1. de Feyter PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up. Circulation 1991; 83: 927-36
2. Lincoff AM, Popma JJ, Ellis SG, et al. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992; 19: 926-35
3. Detre KM, Holmes Jr DR, Holubkov R, et al. Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990; 82: 739-50
4. Uchida Y, Hasegawa K, Kawamura K, et al. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J 1989; 117: 769-76
5. Waller BF, Gorfinkel HJ, Rogers FJ, et al. Early and late morphologic changes in major epicardial coronary arteries after percutaneous transluminal coronary angioplasty. Am J Cardiol 1984; 53: C42-7
6. Waller BF, Pinkerton CA, Orr CM, et al. Morphological observations late (greater than 30 days) after clinically successful coronary balloon angioplasty. Circulation 1991; 83: I28-41
7. Ferguson III JJ. Conventional antithrombotic approaches. Am Heart J 1995; 130: 651-7
8. Wilcox JN, Smith KM, Schwartz SM, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989; 86: 2839-43
9. Rund MM, Smith DD, DeLuca SA, coordinators/investigators. Heparin during coronary angioplasty: are there any rules?. Circulation 1994: I-487
10. McGarry Jr TF, Gottlieb RS, Morganroth J, et al. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J 1992; 123: 1445-51
11. Frierson JH, Dimas AP, Simpfendorfer CC, et al. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn 1993; 28: 279-82
12. Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-74
13. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-5
14. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology 1975; 43: 346-53
15. Vaitkus PT, Herrmann HC, Laskey WK. Management and immediate outcome of patients with intracoronary thrombus during percutaneous transluminal coronary angioplasty. Am Heart J 1992; 124: 1-8
16. Ferguson JJ, Dougherty KG, Gaos CM, et al. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994; 23: 1061-5
17. Narins CR, Hillegass Jr WB, Nelson CL, et al. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996; 93: 667-71
18. Laskey MA, Deutsch E, Barnathan E, et al. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. Am J Cardiol 1990; 65: 1425-9
19. Laskey MA, Deutsch E, Hirshfeld Jr JW, et al. Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. Am J Cardiol 1990; 65: 179-82
20. Satler LF, Leon MB, Kent KM, et al. Strategies for acute occlusion after coronary angioplasty. J Am Coll Cardiol 1992; 19: 936-8
21. Smith Jr SC, Dove JT, Jacobs AK, et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) - executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2001; 37: 2215-38
22. Hillegass WB, Narins CR, Brott BC, et al. Activated clotting time predicts bleeding complications from angioplasty [abstract]. J Am Coll Cardiol 1994; 23: 184A
23. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961-6
24. Boccara A, Benamer H, Juliard JM, et al. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. Eur Heart J 1997; 18: 631-5
25. Koch KT, Piek JJ, de Winter RJ, et al. Safety of low dose heparin in elective coronary angioplasty. Heart 1997; 77: 517-22
26. Vainer J, Fleisch M, Gunnes P, et al. Low-dose heparin for routine coronary angioplasty and stenting. Am J Cardiol 1996; 78: 964-6
27. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-62
28. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614-7
29. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61
30. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96
31. Breddin HK. Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins? Thromb Res 1996; 81: S47-51
32. Turpie AG. Successors to heparin: new antithrombotic agents. Am Heart J 1997; 134: S71-7
33. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52
34. Antman EM. TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators. Am Heart J 1998; 135: S353-60
35. Antman EM, Cohen M. Newer antithrombin agents in acute coronary syndromes. Am Heart J 1999; 138: S563-9
36. Antman EM, Kereiakes DJ. Antithrombotic therapy in unstable angina/non-ST elevation myocardial infarction: the evolving role of low-molecular-weight heparin. J Invasive Cardiol 2000; 12 Suppl E: E1-4; discussion E25-8
37. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". J Invasive Cardiol 2000; 12 Suppl. A: 1A-5A
38. Karsch KR, Preisack MB, Baildon R, et al. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, un-fractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Un-fractionated Heparin and Placebo-Controlled Evaluation. J Am Coll Cardiol 1996; 28: 1437-43
39. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999; 84: 1391-5
40. Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001; 13 (4): 272-8
41. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92
42. Deutsch E, Cohen M, Radley DR, et al. Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina: results of the ESSENCE trial [abstract]. Circulation 1998; 98: I-563
43. Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001; 103: 658-63
44. Kereiakes DJ, Kleiman NS, Fry E, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001; 141: 348-52
45. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000; 35: 1699-712
46. Martin JL, Fry ET, Sanderink G, et al. Reliable anticoagulation with enoxaparin in patients underoing percutaneous coronary intervention: final PEPCI trial results [abstract]. Am J Cardiol 2002; 90: 158H
47. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. Am Heart J 2002; 144: 615-24
48. Bhatt DL, Lincoff AM on behalf of the CRUISE investigators. Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: the results of the CRUISE trial. Circulation 2001; 104: II-384
49. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333: 764-9
50. Bittl JA, Chairman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-9
51. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847-53
52. Lincoff AM, Bittl JA, Kleiman NS, et al. The REPLACE 1 trial: a pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade. J Am Coll Cardiol 2002; 39: I6A, 1053
53. Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93: 215-22
54. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996; 334: 1084-9
55. Leon MG, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. Stem Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-7
56. Mueller C, Buttner JH, Peterson J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. Circulation 2000; 101: 590-3
57. Machraoui A, Germing A, Lindstaedt M, et al. Efficacy and safety of ticlopidine monotherapy versus ticlopidine and aspirin after coronary artery stenting. Follow-up results of a randomized study. J Invasive Cardiol 2001; 13: 431-6
58. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001; 103: 1403-9
59. Seyfarth HJ, Koksch M, Roething G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002 Jan; 143 (1): 118-23
60. Neumann F, Gawaz M, Dickfeld T, et al. Antiplatelet effect of ticlopidine after coronary stenting. J Am Coll Cardiol 1997; 29: 1515-9
61. Gregorini L, Marko J, Fajadet J, et al. Ticlopidine attenuates post stent implantation thrombin generation [abstract]. J Am Coll Cardiol 1996; 27: 334A
62. De Caterina R, Sicari R, Bernini W, et al. Benefit/risk profile of combined antiplatelet therapy with ticlopidine and aspirin. Thromb Haemost 1991; 65: 504-10
63. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000 Aug 8; 102 (6): 624-9
64. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14
65. Smith SC, Dove JT, Jacobs AK, et al. ACC/AHA Guidelines for Percutaneous Coronary Intervention [revision of the 1993 PTCA guidelines - executive summary]. Circulation 2001; 103: 3019-41
66. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33
67. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001; 88: 672-4
68. Assali AR, Salloum J, Sdringola S, et al. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Am J Cardiol 2001; 88: 884-6
69. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 479-84
70. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113: 1-6
71. Lincoff AM, Tcheng JE, Califf RM, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Circulation 1999; 99: 1951-8
72. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354: 2019-24
73. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2001; 37: 2059-65
74. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285: 2468-73
75. O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287: 618-21
76. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94
77. Bhatt DL, Marso SP, Lincoff AM, et al. Abciximab reduces mortality in diabetes following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35: 922-8
78. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767-71